Holen Sie sich die Stockscreener-App
10.60
2.75%
-0.30
Handel nachbörslich:
10.53
-0.07
-0.66%
Schlusskurs vom Vortag:
$10.90
Offen:
$10.74
24-Stunden-Volumen:
540.07K
Relative Volume:
4.52
Marktkapitalisierung:
$175.30M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-3.4754
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+6.11%
1M Leistung:
+25.30%
6M Leistung:
+11.34%
1J Leistung:
-46.36%
1-Tages-Spanne:
$10.22
$11.14
1-Wochen-Bereich:
$8.75
$11.14
52-Wochen-Spanne:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
10.60 | 180.26M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
What high frequency data says about RAPT Therapeutics Inc.July 2025 Reactions & Momentum Based Trading Ideas - Newser
Has RAPT Therapeutics Inc. formed a bullish divergenceJuly 2025 Sector Moves & Daily Volume Surge Signals - Newser
Sentiment analysis tools applied to RAPT Therapeutics Inc.Free Profit Target Stock Opportunity Monitor - Newser
Understanding RAPT Therapeutics Inc.’s price movementForecasting Stock Moves with AI Insights - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionLow Cost High Gain Picks - newsyoung.net
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8. - AInvest
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Will RAPT Therapeutics Inc. continue its uptrendSector Rotation and Stock Opportunity Analysis - Newser
Volume spikes in RAPT Therapeutics Inc. stock – what they meanFree Smart Trade Plans With Risk Protection - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical toolsAlgorithmic Forecast for Swing Trading Picks - Newser
Building trade automation scripts for RAPT Therapeutics Inc.Intelligent Trade Forecast With AI Analytics - Newser
Historical volatility pattern of RAPT Therapeutics Inc. visualizedRisk Aware Trading Ideas with Alert Levels - Newser
Ranking RAPT Therapeutics Inc. among high performing stocks via toolsSmart Swing Picks with Confirmed Signals - Newser
How to forecast RAPT Therapeutics Inc. trends using time seriesPredictable Entry Strategy With Technical Backing - Newser
Multi asset correlation models including RAPT Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Applying Elliott Wave Theory to RAPT Therapeutics Inc.Buy and Hold Position Summary Review - Newser
Published on: 2025-08-09 04:24:12 - beatles.ru
Using AI based signals to follow RAPT Therapeutics Inc.Stock Entry Point Planner with Volume Spike - Newser
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsAlpha Stock Picks with Chart Confirmation - Newser
RAPT Therapeutics Inc. stock daily chart insightsTrade Setup Builder with Custom Alerts - Newser
RAPT Therapeutics Reports Q2 2025 Financial Results: Net Loss of $34.8 Million, Cash and Securities Valued at $169 Million. - AInvest
Full technical analysis of RAPT Therapeutics Inc. stockAlpha Trade Flow With Risk Calibration - Newser
Wells Fargo lowers Rapt Therapeutics stock price target to $38 on model changes - Investing.com Canada
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges - TipRanks
RAPT Therapeutics Reports Q2 2025 Financial Results - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapt Therapeutics reports Q2 EPS (65c), consensus (65c) - TipRanks
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop - MarketScreener
RAPT Therapeutics Reports Second Quarter 2025 Financial Results - The Manila Times
RAPT Therapeutics Q2 revenue up 16% YoY to $7.5mln. - AInvest
RAPT Therapeutics Slashes Losses by $10M, Preps Major Food Allergy Trial Launch - Stock Titan
What machine learning models say about RAPT Therapeutics Inc.Real-Time Signal Tracking with Entry Level - Newser
Clear Street raises Rapt Therapeutics stock price target to $24 on RPT904 potential - Investing.com Canada
Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):